Depomed To Present At UBS Global Healthcare Conference PR Newswire NEWARK, Calif., May 16, 2013 NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York City. The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT) on Tuesday, May 21, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days on the company's website. About Depomed Depomed, Inc.is a specialty pharmaceutical company with three approved and marketed products. Gralise^®(gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor^®(diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults. Glumetza^®(metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized bySantarus, Inc.inthe United States. The company formulates its products and product candidates with its proven, proprietary Acuform^®drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information aboutDepomedmay be found on its website,www.depomed.com. CONTACT: August J. Moretti Depomed, Inc. 510.744.8000 firstname.lastname@example.org SOURCE Depomed, Inc. Website: http://www.depomed.com
Depomed To Present At UBS Global Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.